Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by Zacks Research to “Hold”

Amneal Pharmaceuticals (NASDAQ:AMRX) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Other equities research analysts have also recently issued research reports about the stock. UBS Group lifted their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $22.00 price objective on shares of Amneal Pharmaceuticals in a report on Wednesday, August 26th. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $17.05 on Monday. Amneal Pharmaceuticals has a 52 week low of $9.49 and a 52 week high of $19.26. The stock’s fifty day moving average is $17.76 and its 200-day moving average is $15.00. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a market capitalization of $5.44 billion, a PE ratio of 34.80 and a beta of 1.24.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts expect that Amneal Pharmaceuticals will post 0.94 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director John Kiely sold 50,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the transaction, the director directly owned 210,252 shares in the company, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 413,016 shares of company stock worth $7,216,567 in the last ninety days. 17.30% of the stock is owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP increased its stake in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after buying an additional 624,609 shares during the period. Dimensional Fund Advisors LP boosted its stake in Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock worth $70,723,000 after acquiring an additional 81,546 shares in the last quarter. Morgan Stanley grew its stake in shares of Amneal Pharmaceuticals by 37.5% in the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after buying an additional 1,315,018 shares during the period. Nantahala Capital Management LLC grew its stake in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after acquiring an additional 558,877 shares during the period. Finally, State Street Corp increased its stake in Amneal Pharmaceuticals by 3.4% during the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock valued at $51,791,000 after purchasing an additional 136,662 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.